Korea (Republic of)
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
3.15 (2.67 - 3.75) | 2015 | Modelled | WHO |
2.4 (2.30 - 3) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
4.36 (4.36 - 4.37) | 2013 | Modelled | Schweitzer et al, 2015 |
2.95 (2.81 - 3.10) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
3.46 (3.31 - 3.62) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.56 (3.38 - 3.74) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.53 (3.38 - 3.71) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.5 (3.33 - 3.68) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.52 (3.36 - 3.70) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.6 (3.43 - 3.77) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.69 (3.51 - 3.88) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.77 (3.59 - 3.97) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.79 (3.61 - 4.02) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.82 (3.64 - 4.02) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.88 (3.71 - 4.07) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.96 (3.80 - 4.15) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.03 (3.85 - 4.22) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.06 (3.86 - 4.26) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.1 (3.91 - 4.30) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.2 (4 - 4.41) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.32 (4.11 - 4.55) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.43 (4.19 - 4.68) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.49 (4.23 - 4.76) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.55 (4.29 - 4.83) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.67 (4.40 - 4.95) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.81 (4.52 - 5.12) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.93 (4.62 - 5.27) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.02 (4.69 - 5.38) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.1 (4.78 - 5.46) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.23 (4.89 - 5.59) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.39 (5.03 - 5.77) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.57 (5.17 - 5.96) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.74 (5.32 - 6.18) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.25 (3.10 - 3.42) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Children under-5 years
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.69 (0.49 - 0.94) | 2015 | Modelled | WHO |
0.1 | 2014 | Survey/reported | WHO WPRO, Woodring J et al, 2017 |
0.1 (0.08 - 0.13) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
0.15 (0.11 - 0.19) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.15 (0.11 - 0.20) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.15 (0.11 - 0.20) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.15 (0.11 - 0.20) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.15 (0.11 - 0.20) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.15 (0.11 - 0.21) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.16 (0.12 - 0.22) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.18 (0.13 - 0.23) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.2 (0.15 - 0.25) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.22 (0.16 - 0.28) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.24 (0.18 - 0.30) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.27 (0.20 - 0.35) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.31 (0.23 - 0.40) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.36 (0.27 - 0.46) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.41 (0.31 - 0.53) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.49 (0.37 - 0.63) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.6 (0.45 - 0.78) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.72 (0.53 - 0.93) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.81 (0.59 - 1.04) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.84 (0.61 - 1.09) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.81 (0.60 - 1.04) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.74 (0.55 - 0.95) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.65 (0.49 - 0.84) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.57 (0.44 - 0.75) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.54 (0.41 - 0.72) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.57 (0.43 - 0.74) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.64 (0.49 - 0.84) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.75 (0.58 - 0.98) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.9 (0.68 - 1.18) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.08 (0.81 - 1.41) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.09 (0.08 - 0.12) | 2020 | Modelled | WHO |
Showing out of
Show more
Number of people living with chronic HBV
National
DownloadValue | Year | Type | Source |
---|---|---|---|
1,244,000 (1,155,000 - 1,502,000) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
1,574,690 (1,499,110 - 1,657,840) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
1,659,780 (1,583,540 - 1,744,290) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,758,070 (1,680,160 - 1,842,130) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,793,520 (1,705,300 - 1,882,390) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,763,180 (1,685,330 - 1,848,040) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,728,800 (1,644,240 - 1,815,370) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,720,580 (1,640,560 - 1,805,760) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,738,630 (1,657,700 - 1,822,520) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,766,570 (1,683,920 - 1,855,340) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,785,590 (1,703,580 - 1,877,600) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,782,320 (1,695,140 - 1,882,860) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,778,290 (1,697,780 - 1,870,320) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,797,090 (1,718,690 - 1,882,070) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,825,330 (1,747,580 - 1,908,240) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,847,100 (1,764,330 - 1,933,070) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,851,030 (1,760,800 - 1,944,580) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,859,470 (1,773,490 - 1,949,450) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,894,130 (1,807,530 - 1,985,880) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,939,750 (1,849,080 - 2,039,470) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,978,590 (1,878,620 - 2,090,460) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,995,990 (1,881,890 - 2,116,090) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,012,540 (1,898,580 - 2,132,750) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,051,130 (1,934,180 - 2,174,370) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,099,670 (1,974,760 - 2,232,720) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,143,190 (2,010,760 - 2,286,740) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,170,150 (2,031,470 - 2,321,950) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,197,350 (2,057,480 - 2,351,540) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,243,070 (2,099,700 - 2,396,890) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,301,000 (2,148,220 - 2,459,670) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,361,940 (2,194,130 - 2,528,180) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,417,130 (2,236,340 - 2,599,060) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related death rate
National
DownloadValue (per 100,000) | Year | Type | Source |
---|---|---|---|
21.7 (18.50 - 25.20) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
23.3 (20.44 - 26.33) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
21.95 (19.29 - 24.80) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
20.57 (18.09 - 23.25) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
19.52 (17.15 - 22.10) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
18.92 (16.59 - 21.50) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
18.44 (16.12 - 20.99) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
18.95 (16.69 - 21.48) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
20.3 (18.12 - 22.81) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
22.41 (20.18 - 24.85) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
24.26 (21.90 - 26.78) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
25.62 (23.22 - 28.06) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
25.96 (23.66 - 28.36) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
25.94 (23.55 - 28.23) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
25.59 (23.20 - 27.87) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
24.9 (22.46 - 27.15) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
23.39 (21.03 - 25.61) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
24.04 (21.69 - 26.31) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
22.99 (20.62 - 25.27) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
22.7 (20.31 - 24.99) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
22.23 (19.74 - 24.85) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
22.47 (20.03 - 24.92) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
21.85 (19.32 - 24.47) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
21.51 (18.98 - 24.10) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
20.81 (18.27 - 23.21) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
21.11 (18.60 - 23.74) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
21.07 (18.14 - 23.99) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
20.6 (18.03 - 23.08) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
20.56 (17.91 - 23.13) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
21.7 (18.46 - 25.20) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
21.34 (18.27 - 24.56) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related deaths
National
DownloadValue | Year | Type | Source |
---|---|---|---|
11,974 | 2016 | Modelled | WHO |
11,589 (9,858 - 13,457) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
10,332 (9,064 - 11,673) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
9,804 (8,614 - 11,075) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
9,240 (8,124 - 10,443) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
8,568 (7,513 - 9,739) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
8,805 (7,738 - 9,969) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
8,662 (7,628 - 9,817) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
8,386 (7,331 - 9,543) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
10,363 (9,331 - 11,491) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
9,332 (8,326 - 10,482) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
11,286 (10,185 - 12,455) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
11,987 (10,863 - 13,127) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
12,207 (11,124 - 13,334) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
12,138 (11,008 - 13,223) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
12,254 (11,125 - 13,333) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
11,863 (10,699 - 12,934) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
11,501 (10,379 - 12,588) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
11,247 (10,113 - 12,314) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
11,113 (9,966 - 12,215) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
11,037 (9,877 - 12,150) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
11,001 (9,805 - 12,198) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
10,875 (9,618 - 12,180) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
10,969 (9,740 - 12,260) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
10,811 (9,539 - 12,111) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
10,718 (9,441 - 12,050) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
10,741 (9,354 - 12,080) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
10,669 (9,369 - 11,901) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
10,668 (9,336 - 11,951) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
11,094 (9,552 - 12,632) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
11,318 (9,691 - 13,027) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
11,589 (9,858 - 13,457) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
94 (75 - 117) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
89 (72 - 109) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
86 (72 - 102) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
84 (71 - 98) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
83 (72 - 95) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
83 (72 - 93) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
134 (119 - 149) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
182 (161 - 202) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
99 (87 - 111) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
228 (202 - 252) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
268 (237 - 297) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
293 (258 - 326) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
305 (269 - 339) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
309 (273 - 344) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
310 (274 - 346) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
306 (270 - 342) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
305 (269 - 342) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
303 (265 - 340) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
301 (265 - 337) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
298 (261 - 335) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
292 (253 - 330) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
286 (248 - 322) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
280 (242 - 317) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
276 (239 - 314) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
272 (235 - 312) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
268 (232 - 308) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
264 (224 - 305) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
259 (218 - 301) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
254 (210 - 297) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
247 (202 - 293) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
54 (46 - 63) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Coverage of HepB birth dose
Newborns
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
92 | 2019 | Survey/reported | WHO/UNICEF |
91 | 2018 | Survey/reported | WHO/UNICEF |
93 | 2017 | Survey/reported | WHO/UNICEF |
92 | 2016 | Survey/reported | WHO/UNICEF |
98 | 2015 | Survey/reported | WHO/UNICEF |
92 | 2014 | Survey/reported | WHO/UNICEF |
92 | 2021 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Coverage of 3-dose hepatitis B vaccine
Infants
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
98 | 2019 | Survey/reported | WHO/UNICEF |
98 | 2021 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
DownloadValue | Year | Type | Source |
---|---|---|---|
0 (0 - 0) | 2016 | Survey/reported | Harm Reduction International, 2016 |
Percent of PWID accessing OST
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2001
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.5 (0.30 - 0.50) | 2015 | Modelled | Blach et al, 2017 |
0.64 (0.52 - 0.79) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.63 (0.52 - 0.77) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.62 (0.51 - 0.75) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.59 (0.49 - 0.71) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.56 (0.46 - 0.68) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.53 (0.44 - 0.65) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.51 (0.42 - 0.62) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.49 (0.41 - 0.59) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.48 (0.39 - 0.57) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.47 (0.38 - 0.56) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.47 (0.39 - 0.57) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.5 (0.42 - 0.59) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.54 (0.45 - 0.64) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.57 (0.48 - 0.67) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.59 (0.50 - 0.70) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.61 (0.51 - 0.71) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.61 (0.51 - 0.73) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.62 (0.52 - 0.73) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.63 (0.53 - 0.74) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.64 (0.53 - 0.75) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.66 (0.55 - 0.77) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.68 (0.57 - 0.79) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.71 (0.60 - 0.82) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.72 (0.61 - 0.83) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.72 (0.61 - 0.84) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.71 (0.60 - 0.82) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.69 (0.59 - 0.81) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.68 (0.57 - 0.79) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.65 (0.55 - 0.77) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.62 (0.52 - 0.74) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.6 (0.48 - 0.74) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Women of childbearing age (15–49 years)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.28 (0.18 - 0.32) | 2019 | Modelled | Dugan et al., 2021 |
Prevalence of anti-HCV
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
1.7 | 1992 | Survey/reported | Kim YS et al, 1992 |
0.8 (0.20 - 2.10) | 2014 | Survey/reported | Gower et al, 2014 |
Showing out of
Show more
Newborns
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
1.3 | 2019 | Modelled | Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis |
Men who have sex with men (MSM) Living with HIV
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
4.1 (2.20 - 6.80) | 2019 | Modelled | Jin et al. 2017 |
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
48.4 (42.80 - 54.10) | 2010 | Survey/reported | Min JA et al, 2013 |
Men who have sex with men (MSM)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
4.1 | 2019 | Modelled | Jin et al. 2017 |
Number of people living with chronic HCV (RNA+/cAg)
National
DownloadValue | Year | Type | Source |
---|---|---|---|
231,000 (148,000 - 261,000) | 2015 | Modelled | Blach et al, 2017 |
262,182 (219,937 - 309,192) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
276,450 (232,501 - 324,080) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
288,410 (243,101 - 336,044) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
297,787 (250,947 - 346,311) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
305,249 (259,484 - 354,414) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
311,231 (264,243 - 360,253) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
312,678 (266,794 - 362,264) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
308,252 (260,874 - 358,979) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
299,807 (252,287 - 349,342) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
290,818 (244,105 - 340,613) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
284,600 (236,802 - 334,443) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
281,513 (235,332 - 330,616) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
279,601 (233,316 - 328,398) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
277,477 (231,614 - 327,313) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
274,784 (230,412 - 323,152) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
270,731 (227,208 - 319,596) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
261,433 (220,435 - 308,025) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
247,018 (207,667 - 293,325) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
231,461 (194,300 - 275,308) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
220,130 (182,113 - 264,096) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
218,488 (179,176 - 264,205) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
225,319 (185,699 - 271,018) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
235,507 (195,393 - 284,412) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
247,518 (204,378 - 299,184) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
260,805 (215,295 - 317,257) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
274,368 (225,248 - 336,716) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
294,031 (243,695 - 355,748) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
312,427 (257,759 - 377,889) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
321,229 (264,307 - 390,238) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
328,648 (267,766 - 402,024) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
319,416 (258,929 - 392,964) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Women of childbearing age (15–49 years)
DownloadValue | Year | Type | Source |
---|---|---|---|
34,000 (21,800 - 38,300) | 2019 | Modelled | Dugan et al., 2021 |
HCV-related death rate
National
DownloadValue (Deaths per 100,000) | Year | Type | Source |
---|---|---|---|
6.91 (5.20 - 8.70) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
3.93 (3.09 - 4.99) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
4 (3.19 - 5.01) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.06 (3.27 - 5.05) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.13 (3.35 - 5.14) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.22 (3.42 - 5.21) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.34 (3.53 - 5.32) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.22 (3.42 - 5.18) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.64 (3.79 - 5.64) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.13 (4.19 - 6.20) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.54 (4.54 - 6.66) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.84 (4.75 - 7.03) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.95 (4.81 - 7.18) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
6.01 (4.85 - 7.28) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.98 (4.79 - 7.26) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.87 (4.70 - 7.16) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.68 (4.55 - 6.96) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.68 (4.53 - 6.91) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.7 (4.50 - 7) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.7 (4.52 - 6.94) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.76 (4.50 - 7.11) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.73 (4.49 - 7.05) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.78 (4.51 - 7.17) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.86 (4.57 - 7.28) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.9 (4.59 - 7.34) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.96 (4.65 - 7.40) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
6.04 (4.70 - 7.50) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
6.45 (4.93 - 8.02) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
6.17 (4.79 - 7.68) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
6.67 (5.05 - 8.32) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
6.91 (5.20 - 8.70) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HCV-related deaths
National
DownloadValue | Year | Type | Source |
---|---|---|---|
1,938 | 2016 | Modelled | WHO |
3,689 (2,778 - 4,647) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
3,689 (2,778 - 4,647) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
3,537 (2,681 - 4,414) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
3,398 (2,596 - 4,223) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
3,223 (2,499 - 4,011) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
3,129 (2,433 - 3,882) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
3,054 (2,386 - 3,794) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,993 (2,330 - 3,725) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,944 (2,298 - 3,656) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,879 (2,244 - 3,568) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,843 (2,221 - 3,507) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,803 (2,198 - 3,451) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,774 (2,187 - 3,402) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,753 (2,185 - 3,352) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,730 (2,180 - 3,322) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,718 (2,176 - 3,329) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,796 (2,238 - 3,410) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,838 (2,271 - 3,445) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,840 (2,293 - 3,438) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,798 (2,262 - 3,377) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,732 (2,221 - 3,290) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,575 (2,111 - 3,097) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,371 (1,938 - 2,868) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,135 (1,741 - 2,591) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,983 (1,612 - 2,431) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,918 (1,553 - 2,357) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,911 (1,551 - 2,359) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,862 (1,511 - 2,319) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,822 (1,470 - 2,268) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,786 (1,424 - 2,236) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,743 (1,369 - 2,211) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
DownloadValue | Year | Type | Source |
---|---|---|---|
0 (0 - 0) | 2016 | Survey/reported | Harm Reduction International, 2016 |
Percent of PWID accessing OST
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2001
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
Overview
HBV elimination goal
HCV elimination goal
Prevalence (national)
Modelled
Survey/surveillance
No data available
Hepatitis related deaths (national)
Modelled
HBV
11,589
2019
(9,858 - 13,457)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HBV chart
Modelled
HCV
3,689
2019
(2,778 - 4,647)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HCV chart
Eligible for HBV generic medicines
Eligible for HCV generic medicines